Download PDF
J Pediatr Intensive Care 2015; 04(03): 138-145
DOI: 10.1055/s-0035-1559820
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Efficacy and Safety of Postoperative Dexmedetomidine Administration in Infants and Children Undergoing Cardiac Surgery: A Retrospective Cohort Study

Robert Horvath
1   Children's Heart Clinic, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States
,
Emma F. Halbrooks
2   Critical Care and Cardiovascular Research Center, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States
,
David M. Overman
1   Children's Heart Clinic, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States
2   Critical Care and Cardiovascular Research Center, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States
,
Stefan J. Friedrichsdorf
3   Department of Pain Medicine, Palliative Care and Integrative Medicine, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States
4   Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, United States
› Author Affiliations
Further Information

Publication History

27 June 2014

05 March 2015

Publication Date:
12 August 2015 (online)

   Permissions and Reprints

Abstract

In this retrospective cohort study, we describe efficacy and safety of dexmedetomidine administration in the cardiac intensive care unit, in children undergoing cardiac surgery. This study consisted of pediatric patients 3 days to 17.5 years of age, undergoing cardiac surgery from April 2010 to April 2011. In addition to a scheduled opioid, usually fentanyl, 107 patients received dexmedetomidine postoperatively, including 19 (18%) patients diagnosed with trisomy 21 and 9 (8%) neonates/newborns. Median dexmedetomidine starting dose was 0.45 µg/kg/h and overall median dose higher than previously published, ranging from 0.8 µg/kg/h to 2.17 µg/kg/h. We compared infants (younger than 1 year) with older children (1–17 years of age). Median duration of administration was 1.6 days (0–23.9 days) and duration to extubation in infants was 46.5 hours, and in the older children it was 22.6 hours. Seven patients (6.5%) were discontinued dexmedetomidine due to adverse events, most commonly bradycardia. Neonates experienced more pronounced heart rate reduction (no bradycardia) and received lower maintenance doses than older infants (0.56 vs. 0.77 µg/kg/h). The face, leg, activity, cry, consolability pain scale and the state behavioral scale scores indicated adequate sedation and good analgesia. The most common adverse reaction postdiscontinuation was agitation, more frequent in the infant group (20 vs. 11.2%). Thirty patients (28.3%) received prolonged infusion (>72 hours). Patients with and without trisomy 21 did not differ with dose, safety, efficacy, or adverse events. Dexmedetomidine, as part of multimodal management, appears to be a safe, efficacious agent providing analgesia and sedation throughout all pediatric age groups following cardiac surgery. Overall, dexmedetomidine is well tolerated and safe with higher doses than previously noted, and is well tolerated by neonates, infants, and patients with trisomy 21. Withdrawal effects were noted in patients following prolonged infusion.

Keywords

dexmedetomidine - pediatric cardiac surgery - pain - sedation - trisomy 21 - withdrawal
 

  • References

  • 1 Precedex (Dexmedetomidine) [package insert]. Lake Forest, IL: Hospira, Inc.; 2008
    Google Scholar
  • 2 Chrysostomou C, Sanchez De Toledo J, Avolio T , et al. Dexmedetomidine use in a pediatric cardiac intensive care unit: can we use it in infants after cardiac surgery?. Pediatr Crit Care Med 2009; 10 (6) 654-660
    CrossrefPubMedGoogle Scholar
  • 3 Petroz GC, Sikich N, James M , et al. A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. Anesthesiology 2006; 105 (6) 1098-1110
    CrossrefPubMedGoogle Scholar
  • 4 Chrysostomou C, Di Filippo S, Manrique AM , et al. Use of dexmedetomidine in children after cardiac and thoracic surgery. Pediatr Crit Care Med 2006; 7 (2) 126-131
    CrossrefPubMedGoogle Scholar
  • 5 Jenkins KJ. Risk adjustment for congenital heart surgery: the RACHS-1 method. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2004; 7: 180-184
    CrossrefPubMedGoogle Scholar
  • 6 Gaies MG, Gurney JG, Yen AH , et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med 2010; 11 (2) 234-238
    CrossrefPubMedGoogle Scholar
  • 7 Merkel SI, Voepel-Lewis T, Shayevitz JR, Malviya S. The FLACC: a behavioral scale for scoring postoperative pain in young children. Pediatr Nurs 1997; 23 (3) 293-297
    PubMedGoogle Scholar
  • 8 Curley MA, Harris SK, Fraser KA, Johnson RA, Arnold JH. State Behavioral Scale: a sedation assessment instrument for infants and young children supported on mechanical ventilation. Pediatr Crit Care Med 2006; 7 (2) 107-114
    CrossrefPubMedGoogle Scholar
  • 9 Su F, Nicolson SC, Gastonguay MR , et al. Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. Anesth Analg 2010; 110 (5) 1383-1392
    CrossrefPubMedGoogle Scholar
  • 10 Chrysostomou C, Schulman SR, Herrera Castellanos M , et al. A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. J Pediatr 2014; 164 (2) 276-82.e1 , 3
    CrossrefPubMedGoogle Scholar
  • 11 Burbano NH, Otero AV, Berry DE, Orr RA, Munoz RA. Discontinuation of prolonged infusions of dexmedetomidine in critically ill children with heart disease. Intensive Care Med 2012; 38 (2) 300-307
    CrossrefPubMedGoogle Scholar
  • 12 Lam F, Bhutta AT, Tobias JD, Gossett JM, Morales L, Gupta P. Hemodynamic effects of dexmedetomidine in critically ill neonates and infants with heart disease. Pediatr Cardiol 2012; 33 (7) 1069-1077
    CrossrefPubMedGoogle Scholar
  • 13 Gupta P, Whiteside W, Sabati A , et al. Safety and efficacy of prolonged dexmedetomidine use in critically ill children with heart disease. Pediatr Crit Care Med 2012; 13 (6) 660-666
    CrossrefPubMedGoogle Scholar
  • 14 Mason KP, Zurakowski D, Zgleszewski SE , et al. High dose dexmedetomidine as the sole sedative for pediatric MRI. Paediatr Anaesth 2008; 18 (5) 403-411
    CrossrefPubMedGoogle Scholar
  • 15 Lam F, Ransom C, Gossett JM , et al. Safety and efficacy of dexmedetomidine in children with heart failure. Pediatr Cardiol 2013; 34 (4) 835-841
    CrossrefPubMedGoogle Scholar
  • 16 Hosokawa K, Shime N, Kato Y , et al. Dexmedetomidine sedation in children after cardiac surgery. Pediatr Crit Care Med 2010; 11 (1) 39-43
    CrossrefPubMedGoogle Scholar
  • 17 Tobias JD, Berkenbosch JW. Sedation during mechanical ventilation in infants and children: dexmedetomidine versus midazolam. South Med J 2004; 97 (5) 451-455
    CrossrefPubMedGoogle Scholar
  • 18 Pichot C, Ghignone M, Quintin L. Dexmedetomidine and clonidine: from second- to first-line sedative agents in the critical care setting?. J Intensive Care Med 2012; 27 (4) 219-237
    CrossrefPubMedGoogle Scholar
  • 19 Iirola T, Aantaa R, Laitio R , et al. Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients. Crit Care 2011; 15 (5) R257
    CrossrefPubMedGoogle Scholar
  • 20 Bejian S, Valasek C, Nigro JJ, Cleveland DC, Willis BC. Prolonged use of dexmedetomidine in the paediatric cardiothoracic intensive care unit. Cardiol Young 2009; 19 (1) 98-104
    CrossrefPubMedGoogle Scholar
  • 21 O'Mara K, Gal P, Wimmer J , et al. Dexmedetomidine versus standard therapy with fentanyl for sedation in mechanically ventilated premature neonates. J Pediatr Pharmacol Ther 2012; 17 (3) 252-262
    PubMedGoogle Scholar
  • 22 Kalyanaraman M, Costello JL, Starr JP. Use of dexmedetomidine in patients with trisomy 21 after cardiac surgery. Pediatr Cardiol 2007; 28 (5) 396-399
    CrossrefPubMedGoogle Scholar
  • 23 Van Driest SL, Shah A, Marshall MD , et al. Opioid use after cardiac surgery in children with Down syndrome. Pediatr Crit Care Med 2013; 14 (9) 862-868
    CrossrefPubMedGoogle Scholar